| 摘要 |
Disclosed is the citrate salt of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile (the compound of formula 1). Also disclosed is the above salt in crystalline form. Also disclosed is a process for preparing the above salt or crystal form. Also disclosed is the use of the above salt for treating cognitive disorders, dementia, Cognitive Deficit in Schizophrenia, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, Frontotemporal dementia, Frontotemporal dementia Parkinson's Type, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, corticobasal degeneration, traumatic brain injury, dementia pugilistica, Alzheimer's Disease, Down's syndrome, vascular dementia, Parkinson's Disease, postencephelatic parkinsonism, dementia with Lewy bodies, HIV dementia, Huntington's Disease, amyotrophic lateral sclerosis, motor neuron diseases, Creuztfeld-Jacob's disease, prion diseases, attention deficit disorder, attention deficit hyperactivity disorder, affective disorders, Bipolar Disorder including acute mania, bipolar depression, bipolar maintenance, major depressive disorders including depression, major depression, mood stabilization, schizoaffective disorders including schizophrenia, dysthymia, bone related disorders or conditions, osteoporosis, and for increasing bone formation, increasing cancellous bone formation and/or new bone formation, increasing bone mineral density, reducing the incidence of fracture or enhancing fracture healing.
|
